

Corindus

Vascular Robotics

Precision Vascular Robotics

Corindus Vascular Robotics (CVRS)
September 2018




Forward Looking Statements

This presentation contains “forward-looking statements” (as such term is defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended), and information relating to the company, that are based on the current beliefs of, and assumptions made by our management and the information currently available to our management. Forward-looking statements relate to expectations concerning matters that are not historical facts. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict," "opinion," "will" and similar expressions and their variants, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to statements related to our expected business, products and adoption of robotic medical procedures, including AI/automation, telestenting and remote procedures, and expanding our technology platform for use in the neurovascular market, results of operations, future financial condition, ability to increase our revenues, and similar matters. These forward-looking statements should be considered in light of various important factors, including, without limitation, our ability to expand our technology platform and achieve the advances necessary for telestenting and remote procedures, including in humans; our ability to expand our technology platform for use in other segments of the vascular intervention market, including neurointerventional and other more complex cardiac interventions, obtaining necessary regulatory approvals for the use on humans and marketing of our products in the United States and in other countries, the rate of adoption of our CorPath System and the rate of use of our cassettes; risks associated with market acceptance, including pricing and reimbursement; our ability to enforce our intellectual property rights; our need for additional funds to support our operations; our ability to manage expenses and cash flow; factors relating to engineering, regulatory, manufacturing, sales and customer service challenges; potential safety and regulatory issues that could slow or suspend our sales; the effect of credit, financial and economic conditions on capital spending by our potential customers; the impact of global and regional economic and credit market conditions on health care spending; health care reform legislation in the United States and its impact on hospital spending, reimbursement and fees which will be levied on certain medical device revenues, decreases in hospital admissions and actions by payers to limit or manage surgical procedures timing and success of product development and market acceptance of developed products, procedure counts; regulatory approvals, clearances and restrictions; guidelines and recommendations in the health care and patient communities, intellectual property positions and litigation, competition in the medical device industry and in the specific markets of surgery in which we operate, the inability to meet demand for products, the results of legal proceedings to which we are or may become a party, product liability and other litigation claims, adverse publicity regarding our company and safety of our products and the adequacy of training; our ability to expand in foreign markets; and other risk factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which are based on current expectation and are subject to risks, uncertainties; and assumptions that are difficult to predict, including those risk factors described in the Company's Annual Report on Form 10-K for the fiscal year ended on December 31, 2017. Our actual results may differ materially and adversely from those expressed in any forward-looking statements. We undertake no obligation to publicly update or release any revisions to these forward-looking statements except as required by law.

Corindus: An Overview


A Global Leader in Robotic-assisted Vascular Interventions

Commercialization of CorPath GRX in 2017 was a Key Inflection Point, Accelerating Physician Adoption




Corindus' Robotic Technology

Potential to be First Disruptive Treatment Option in Vascular Medicine in 40+ years



Adding Value in PCI & Peripheral Across Key Stakeholders

Paradigm Shift in Place Will Drive Adoption



¹ Smilowitz N, et al. Robotic-Enhanced PCI Compared to the Traditional Manual Approach. J Invasive Cardiol, 2014;26(7):318-321.


² Campbell PT, et al. The Impact of Precise Robotic Lesion Length Measurement on Stent Length Selection: Ramification for stent savings. Cardiovasc Revasc Med. 2015;pii:S1553-8389.

Substantial Market Opportunity

Targeting Subsets Where Technology Platform Adds Value

PCI

3+ M Procedures WW¹
(~900K US / ~2.2M OUS)




Target Market:

US (Complex) / OUS (Simple / Complex)

PERIPHERAL

Over 2+ M Procedures WW¹
(~875K US / ~1.3M OUS)




Target Market:

CLI (BTK)

NEURO

~900K Stroke Incidence US³



Target Market:

Expand TAM with remote access

¹ Millennium Research Group. Reduced OUS market size to reflect target markets only.

² Decision Resources Group

³ Company estimates based on third party report


Robotics Integrates Into High Tech Care Models

Allow Procedures to be Performed

Devices



Artificial Intelligence



Imaging



Navigation



Robotics



Remote



Problem



- High percentage of procedure time is dedicated to wire manipulation
- Varying skill levels among operators



Strategy

- Create algorithms based on techniques of highly skilled operators
- Reduced procedure time may positively impact patient outcomes




Rotate on Retract



Software algorithm that automatically rotates wire upon joystick retraction

53% reduction in wiring time with reduced variability



Continued development of technIQ™ Series


New automated movements aimed at reducing navigation time, increasing success of lesion crossing

Addressing Unmet Needs

Realizing remote capabilities

Problem

- Access to treatment in remote/rural locations
- Aging patient population
- Shortage of skilled specialists
- **Emergent procedures:** Time to treatment is critical




Strategy

- Increase access to care & reduce time to treatment
- Expand capable facility footprint
- Enable tele-proctoring

Key Accomplishments

- Initiated preclinical studies with the Mayo Clinic
- Rapid technology development & end user testing
- Remote porcine test case from 100+ miles away



Dr. Ryan Madder conducting first successful telestent procedure in porcine model from Ludington, MI

Neurovascular Steering Committee / Milestones

Product Optimization for Remote Stroke Underway

Steering Committee

CMO, Neuro



Aquilla S. Turk, D.O.
Medical University of South Carolina



Ricardo A. Hanel, M.D. PhD
Baptist Health System



Tudor G. Jovin, M.D.
University of Pittsburgh Medical Center



J. Mocco, M.D.
Mt. Sinai Hospital




Raul G. Nogueira, M.D.
Grady Memorial Hospital



Vitor Mendes Pereria, M.D.
Toronto Western Hospital



Adnan Siddiqui, M.D.
Toshiba Stroke & Vascular Research Center



Satoshi Tateshima, M.D.
Ronald Reagan UCLA Medical Center



Raymond D. Turner, M.D.
Medical University of South Carolina

2018

2019

KOL Neuro Summit

Steering Committee Formed

Multiple Neuro Animal Lab Studies


CorPath GRX FDA Submission¹

GRX Neuro Product Launch¹

Neuroendovascular Remote Robotic Development¹

Stroke: A Serious and Costly Problem


**WHEN IT COMES TO STROKE,
TIME LOST IS BRAIN LOST**



American Heart Association American Stroke Association
life is why™ Together to End Stroke™

- Stroke ranks the #5 cause of death in the US (accounts for **1 in 19** deaths)¹
- > 7 million stroke survivors, **two-thirds of which live with a moderate-to-severe disability**¹
- Each passing minute during stroke results in the **loss of ~2 million neurons**. Each passing second ages a patient by 9 hours¹

Remote Access Capabilities May Significantly Increase TAM




- Time to treatment is key in the stroke market
- Current treatment paradigm **requires treatment within a 24 hour window**
- Lack of **proximity to facilities and limited number of specialists** leads to a meaningful % of patients not being treated


CVRS' Remote Access Capabilities has Opportunity to Significantly Expand Treatable Patients: TIME IS BRAIN

Financials Snapshot


Revenue



GRX Installed Base



Cassette Sales



~Cash balance of \$34.3M, Debt of \$11.6M, 188.9M shares outstanding and 1M preferred (convertible to 20.2M common shares) as of June 30, 2018

Sites that upgraded from a CorPath 200 to a CorPath GRX have, on average, nearly doubled the percentage of PCI procedures performed robotically

Clinical Catalysts: Next 12-24 Months

Key Expected Milestones for Clinical Development

Remote

- Live remote PCI at TCT 2018
- First-in-human completed by year-end 2018 in India
- Planned US clinical trials

Neuro

- FDA submission for neuro indication by year-end 2018 or early 2019
- Partnership for commercialization and co-development
- FDA clearance and launch of CorPath GRX for neuro in first half 2019

- Significant progress in technology development and clinical expansion is creating a burning platform for hospitals to build a robotic program
- AI / automation and remote access have the potential to add significant value to hospitals, patients, and doctors in the interventionalist market
- Remote capabilities have the ability to increase TAM of the stroke market with opportunity to further expand the addressable market post launch of the next generation robot
- Strong intellectual property portfolio / first mover advantage

Corindus is a Leading Vascular Robotics Company with Opportunities in Coronary, Peripheral, and Neurovascular Markets